Prolia denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for prolia are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Prolia as "Not FDA-Approved"

This denial is almost always a coding or routing error. Denosumab (Prolia) holds FDA approval for specific bone-loss indications; the approval record is publicly searchable on the FDA website. UHC's own coverage policies acknowledge FDA-approved indications for Prolia. When you see a "not FDA-approved" denial, the insurer's system typically flagged the submitted diagnosis code, the route of administration, or the prescribing specialty as inconsistent with an approved indication — not that the drug itself lacks approval.

This type of denial is among the most winnable on appeal because the factual predicate is publicly verifiable.

## Your Federal Appeal Rights

Under ACA §2719 (non-grandfathered commercial plans) and ERISA §503 (employer-sponsored plans), you have a right to a full-and-fair internal review followed by binding external review. Key timelines:

• Internal appeal deadline: Typically 180 days from the denial notice — check your Explanation of Benefits.
• External review window: Roughly four months after exhausting internal appeals (plan documents govern exact dates).
• Expedited external review: Available when a standard timeline would seriously jeopardize your health — request it explicitly and in writing.

## The Appeal Process

1. Request the complete denial letter and the clinical criteria UHC applied (you are entitled to these under ERISA). 2. Pull the current FDA prescribing label for Prolia (available at DailyMed, fda.gov) and confirm your prescribed indication appears in the approved labeling. 3. Submit a corrected prior-authorization request with the precise diagnosis code that matches an FDA-approved indication, accompanied by your prescriber's letter. 4. If internal appeal is denied, file for external review through your state's Department of Insurance or the federal process — the denial letter must include the required instructions.

## Documentation to Gather

• Diagnosis confirmation: ICD-10 code in the chart aligned with the FDA-approved indication on the label.
• Prescriber letter: Explains why the prescribed indication is FDA-approved and medically necessary for this patient.
• FDA label excerpt: The relevant approved indication, printed directly from fda.gov or DailyMed.
• UHC's published coverage policy: Print the current version, highlight the FDA-approval language, and note that your case meets it.

## Criteria-Mapping Structure

Copy each requirement stated in UHC's coverage policy into a table. In the column beside each requirement, cite the exact chart entry, lab date, or prescriber statement that satisfies it. Attach the FDA label page confirming the indication is approved. This side-by-side format removes ambiguity and forces the reviewer to address each criterion individually rather than issue a blanket denial.